BRPI1011567A2 - método de tratar fragilidade - Google Patents

método de tratar fragilidade

Info

Publication number
BRPI1011567A2
BRPI1011567A2 BRPI1011567A BRPI1011567A BRPI1011567A2 BR PI1011567 A2 BRPI1011567 A2 BR PI1011567A2 BR PI1011567 A BRPI1011567 A BR PI1011567A BR PI1011567 A BRPI1011567 A BR PI1011567A BR PI1011567 A2 BRPI1011567 A2 BR PI1011567A2
Authority
BR
Brazil
Prior art keywords
treating frailty
frailty
treating
Prior art date
Application number
BRPI1011567A
Other languages
English (en)
Inventor
Helenius Jan Kloosterboer
Marjanna Prins
Original Assignee
Organext Res B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42016317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011567(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organext Res B V filed Critical Organext Res B V
Publication of BRPI1011567A2 publication Critical patent/BRPI1011567A2/pt
Publication of BRPI1011567B1 publication Critical patent/BRPI1011567B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI1011567-6A 2009-08-24 2010-08-23 Composição farmacêutica BRPI1011567B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09168522A EP2289555A1 (en) 2009-08-24 2009-08-24 Method of treating frailty
EP09168522.2 2009-08-24
PCT/NL2010/050524 WO2011025368A1 (en) 2009-08-24 2010-08-23 Method of treating frailty

Publications (2)

Publication Number Publication Date
BRPI1011567A2 true BRPI1011567A2 (pt) 2016-04-05
BRPI1011567B1 BRPI1011567B1 (pt) 2019-05-14

Family

ID=42016317

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011567-6A BRPI1011567B1 (pt) 2009-08-24 2010-08-23 Composição farmacêutica

Country Status (23)

Country Link
US (1) US10543217B2 (pt)
EP (2) EP2289555A1 (pt)
JP (2) JP2013502457A (pt)
KR (1) KR20120053987A (pt)
CN (1) CN102421450B (pt)
AU (1) AU2010287043B2 (pt)
BR (1) BRPI1011567B1 (pt)
CA (1) CA2759815C (pt)
CL (1) CL2011002863A1 (pt)
CO (1) CO6460777A2 (pt)
DK (1) DK2470214T3 (pt)
ES (1) ES2425095T3 (pt)
IL (1) IL216456A (pt)
MX (1) MX2011011905A (pt)
MY (1) MY162621A (pt)
NZ (1) NZ596057A (pt)
PL (1) PL2470214T3 (pt)
PT (1) PT2470214E (pt)
RU (1) RU2635541C2 (pt)
SG (1) SG176135A1 (pt)
UA (1) UA107928C2 (pt)
WO (1) WO2011025368A1 (pt)
ZA (1) ZA201108056B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101970893B1 (ko) 2017-10-18 2019-04-19 동아대학교 산학협력단 노쇠 여부 스크리닝 장치
CN109364034B (zh) * 2018-11-26 2021-05-04 正大制药（青岛）有限公司 一种骨化三醇制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
JP3708115B2 (ja) * 1991-05-06 2005-10-19 ザ プロクター アンド ギャンブル カンパニー 混合カルシウム及びビタミンｄ補給品
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US7261905B2 (en) * 1999-04-07 2007-08-28 Pure Bioscience Disinfectant and method of making
US6638239B1 (en) * 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
GB0307728D0 (en) 2003-04-03 2003-05-07 Tesla Engineering Ltd Coil structure for magnetic resonance imaging
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
FR2860236B1 (fr) * 2003-09-25 2006-01-06 Theraptosis Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique
CA2607901C (en) * 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
US8426391B2 (en) * 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
CA2558202A1 (en) * 2006-09-14 2006-11-23 Reinhold W. Vieth Vitamin d compositions and method of administration to infants
RU2363488C1 (ru) * 2007-11-26 2009-08-10 Закрытое акционерное общество "Эксесс Байосаинс" Фармацевтическая композиция на основе пептида, регулирующего нарушения ангиогенеза, и способ ее применения
US9259430B2 (en) * 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
RU2410392C2 (ru) * 2009-02-16 2011-01-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН Дипептидные миметики нейротрофинов ngf и bdnf

Also Published As

Publication number Publication date
ES2425095T3 (es) 2013-10-11
RU2635541C2 (ru) 2017-11-13
JP6279529B2 (ja) 2018-02-14
SG176135A1 (en) 2011-12-29
MX2011011905A (es) 2012-01-30
CN102421450A (zh) 2012-04-18
NZ596057A (en) 2013-07-26
EP2289555A1 (en) 2011-03-02
CA2759815A1 (en) 2011-03-03
PT2470214E (pt) 2013-08-27
IL216456A0 (en) 2012-01-31
US10543217B2 (en) 2020-01-28
UA107928C2 (en) 2015-03-10
ZA201108056B (en) 2012-07-25
EP2470214B1 (en) 2013-05-15
KR20120053987A (ko) 2012-05-29
AU2010287043B2 (en) 2014-11-06
JP2013502457A (ja) 2013-01-24
JP2016011313A (ja) 2016-01-21
MY162621A (en) 2017-06-30
WO2011025368A1 (en) 2011-03-03
CN102421450B (zh) 2015-09-09
RU2011146830A (ru) 2013-10-10
BRPI1011567B1 (pt) 2019-05-14
IL216456A (en) 2017-04-30
US20120196837A1 (en) 2012-08-02
DK2470214T3 (da) 2013-08-12
CO6460777A2 (es) 2012-06-15
CL2011002863A1 (es) 2012-04-13
AU2010287043A1 (en) 2011-11-10
PL2470214T3 (pl) 2013-12-31
EP2470214A1 (en) 2012-07-04
CA2759815C (en) 2018-06-12

Similar Documents

Publication Publication Date Title
BRPI1013317A2 (pt) método de cimentação
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
FI20090389A0 (fi) Menetelmä
BRPI0910854A2 (pt) métodos de tratamento
BR112013012485A2 (pt) método de tratamento com inibidor braf
BRPI1012526A2 (pt) método
BRPI1010705A2 (pt) método
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
DK2326332T3 (da) Fremgangsmåde til behandling af sygdomme
BR112012003956A2 (pt) método de tratar água residual
BR112013022820A2 (pt) método de tratamento
BRPI1012532A2 (pt) método
DK2453858T3 (da) Fremgangsmåde
DK2473482T3 (en) Methods of treating orthomyxoviral infections
DK2501381T3 (da) Behandling af atrieflimmer
BRPI0917417A2 (pt) mnétodos de tratar deficiência cognitiva
BRPI1009350A2 (pt) método
BRPI1010121A2 (pt) método de tratamento biológico
BRPI1014394A2 (pt) método de tratamento de vidro
BR112012004071A2 (pt) tratamento de petróleo
BRPI1011567A2 (pt) método de tratar fragilidade
DK2393834T3 (da) Fremgangsmåde til oprensning
UY33136A (es) Tropinonabencilaminas como inhibidores de la beta-triptasa
BR112013015226A2 (pt) método para o tratamento de corpos de água

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/08/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2685 DE 21-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.